Video
Author(s):
Michael J. Wagner, MD, discusses molecular pathways that are becoming relevant in angiosarcoma.
Michael J. Wagner, MD, assistant professor, University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, discusses molecular pathways that are becoming relevant in angiosarcoma.
Recent breakthroughs in genetic sequencing have led to the identification of molecular pathways that drive angiosarcoma, according to Wagner.
Investigators are exploring treatments targeting the MAPK pathway, as well as PIK3A, and mTOR, Wagner adds. Developing new agents can be challenging in angiosarcoma, but this knowledge may allow physicians to explore off-label regimens, Wagner concludes.